查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1727073

妊娠高血压肾臟病诊断的全球市场 - 市场考察，竞争情形，市场预测(2032年)

Preeclampsia Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2032
出版日期: | 出版商: DelveInsight | 英文 150 Pages | 商品交期: 2-10个工作天内

价格

预计在 2025-2032 年预测期内，全球子痫前症诊断市场规模将以 3.67% 的复合年增长率成长。市场成长主要源自于子痫前症及其相关风险因素的盛行率不断上升，以及孕妇和医护人员对此疾病认知度的不断提升。此外，预计在 2025-2032 年预测期内，主要市场参与者持续的产品开发活动将进一步促进市场扩张。

子痫前症诊断市场动态

全球先兆子痫盛行率的不断上升，正在显着推动整个子痫前症诊断市场的发展。根据世界卫生组织 (WHO) (2024) 的数据，子痫前症影响全球 2-8% 的怀孕。这种妊娠相关併发症的特征是高血压和器官损害，主要发生在妊娠20週后，许多女性都会面临这种情况，因此对早期和准确检测方法的需求正在稳步增长。

此外，英国产科监测系统 (UKOSS) 的一项研究发现，严重肥胖患者的子痫前症盛行率为 9%，而非肥胖对照组的盛行率为 2%。此外，根据子痫前症基金会 (2024) 提供的数据，妊娠高血压疾病 (HDP)，包括妊娠高血压、慢性高血压、子痫前症和子痫等疾病，影响全球约 5-10% 的怀孕。

子痫前症是 HDP 的主要和最严重的形式，通常以血压升高和器官系统（尤其是肝臟和肾臟）受损的迹象为特征。由于妊娠期子痫（HDP）持续构成重大健康风险，预计全球先进子痫前症诊断技术的采用将持续增加。孕产妇年龄增长、肥胖、糖尿病、高血压和多胎妊娠等因素是增加子痫前症风险的主要因素。因此，全球子痫前症患者数量正在增加，预计将推动子痫前症诊断市场的成长。

提高孕妇的认知度也是子痫前症诊断市场的主要成长动力。例如，为了纪念2025年1月23日的孕产妇健康宣传日，先兆子痫基金会与 "病患与目标" （Patients & Purpose）组织合作，发起了GAP-SPIRIN活动。这项实证教育倡议旨在推广使用低剂量阿斯匹灵预防子痫前症，并解决孕产妇健康差距问题。

该活动结合了黑人孕妇面临的独特课题资讯和低剂量阿斯匹灵预防指南，帮助医疗保健提供者更好地管理子痫前症的风险。子痫前症是一种严重的、可能危及生命的妊娠期和产后高血压疾病。它是孕产妇健康危机的核心问题，对黑人母亲的影响尤其严重，发生率高达 60%。

市场主要参与者开发的创新诊断测试正在显着促进市场成长。 2022 年 5 月，Mirvie 宣布其 Mirvie 子痫前症测试获得美国 FDA 突破性设备称号。这项突破性的测试旨在在症状出现之前对女性患有子痫前症的风险进行个别评估。此检测由专有的 Mirvie RNA 平台提供，可分析每个妊娠特有的生物讯号，预测不可预见的併发症风险，从而实现更早、更个人化的临床干预。

儘管存在这些充满希望的成长动力，但子痫前症诊断市场仍面临课题。患者和医疗保健提供者的认知度有限，以及子痫前症诊断测试​​准确性的局限性，都是可能在预测期内阻碍市场成长的重大阻碍因素。

本报告研究了全球子痫前症诊断市场，并提供了市场规模和预测、过去三年产品/技术发展、市场主要参与者以及可用机会等资讯。

本报告提供全球妊娠高血压肾臟病诊断市场相关调查分析，提供市场规模与预测，过去3年的产品/技术开发，市场主要企业，可利用的机会等资讯。

目录

第1章 妊娠高血压肾臟病诊断市场报告的简介

第2章 妊娠高血压肾臟病诊断市场摘要整理

  • 市场概要

第3章 竞争情形

第4章 法规分析

  • 美国
  • 欧洲
  • 日本
  • 中国

第5章 妊娠高血压肾臟病诊断市场主要原因的分析

  • 妊娠高血压肾臟病诊断市场促进因素
  • 妊娠高血压肾臟病诊断市场阻碍因素与课题
  • 妊娠高血压肾臟病诊断市场机会

第6章 妊娠高血压肾臟病诊断市场上波特的五力分析

第7章 妊娠高血压肾臟病诊断市场评估

  • 检体类别
    • 血液检验
    • 尿液检查
  • 各产品类型
    • 试剂·套件
    • 器具
  • 检验方式
    • 实验室为基础的检验
    • 就地检验(POCT)
  • 各终端用户
    • 医院
    • 专门诊所
    • 诊断中心
    • 其他
  • 地区
    • 北美
    • 欧洲
    • 亚太地区
    • 其他地区

第8章 妊娠高血压肾臟病诊断市场企业与产品的简介

  • F. Hoffmann-La Roche Ltd.
  • Thermo Fisher Scientific Inc.
  • Labcorp
  • PerkinElmer
  • ARUP Laboratories
  • Siemens Healthineers AG
  • QuidelOrtho Corporation
  • Revvity
  • Randox Laboratories
  • CERCA Biotech

第9章 KOL的见解

第10章 计划方法

第11章 关于DelveInsight

第12章 免责声明，咨询方式

Product Code: DIMDCL0862

Preeclampsia Diagnostics Market by Sample Type (Blood Test and Urine Test), Product Type (Reagents & Kits and Instruments), Mode of Testing (Laboratory-based Testing and Point-of-care Testing (POCT)), End-User (Hospitals, Specialty Clinics, Diagnostic Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising cases of preeclampsia worldwide & associated risk factors and growing awareness among pregnant women and healthcare professionals

The preeclampsia diagnostics market is estimated to grow at a CAGR of 3.67% during the forecast period from 2025 to 2032. The growth of the preeclampsia diagnostics market is primarily driven by the increasing incidence of preeclampsia and its associated risk factors, along with rising awareness among pregnant women and healthcare professionals. Additionally, ongoing product development initiatives by key market players are expected to further contribute to the market's expansion during the forecast period from 2025 to 2032.

Preeclampsia Diagnostics Market Dynamics:

The rising prevalence of preeclampsia globally is significantly boosting the overall market for preeclampsia diagnostics. According to the data provided by the World Health Organization (2024), preeclampsia affects 2-8% of pregnancies worldwide. As more women face this pregnancy-related complication, primarily marked by high blood pressure and signs of organ damage usually occurring after the 20th week of gestation, the need for early and accurate detection methods is steadily increasing.

Additionally, the UK Obstetric Surveillance System (UKOSS) study showed an incidence of preeclampsia of 9% in severely obese patients compared to 2% of nonobese controls. Also, according to the data provided by the Preeclampsia Foundation Organization (2024), hypertensive disorders of pregnancy (HDPs), which include conditions such as gestational hypertension, chronic hypertension, preeclampsia, and eclampsia, affected approximately 5-10% of all pregnancies worldwide.

Preeclampsia is a major and most severe form of HDP, often characterized by elevated blood pressure and signs of damage to organ systems, particularly the liver and kidneys. As HDPs continue to pose significant health risks, the adoption of advanced preeclampsia diagnostic technologies is expected to boost across the globe. Factors such as increasing maternal age, obesity, diabetes, hypertension, and multiple pregnancies are key contributors to the growing risk of developing preeclampsia. Therefore, the rising cases of preeclampsia across the globe are expected to boost the growth of the preeclampsia diagnostics market.

Increasing awareness among pregnant women is another key factor driving the growth of the preeclampsia diagnostics market. For example, in January 2025, in recognition of Maternal Health Awareness Day on January 23rd, the Preeclampsia Foundation, in collaboration with Patients & Purpose, launched the "GAP-SPIRIN" campaign. This evidence-based educational initiative promotes the use of low-dose aspirin to help prevent preeclampsia and address disparities in maternal health.

The campaign combines information on the unique challenges faced by Black expectant mothers with guidance on low-dose aspirin prophylaxis, equipping healthcare providers to better manage preeclampsia risk. Preeclampsia is a severe hypertensive condition that can pose life-threatening risks during pregnancy and the postpartum period. It is a central issue in the maternal health crisis, disproportionately affecting Black mothers, who are 60% more likely to develop the condition.

The development of innovative diagnostic tests by key market players is significantly contributing to market growth. A notable example is Mirvie, which in May 2022 announced it received U.S. FDA Breakthrough Device designation for its Mirvie Preeclampsia Test. This groundbreaking test is designed to assess a woman's individualized risk of developing preeclampsia before symptoms arise. It is powered by the proprietary Mirvie RNA platform, which analyzes the unique biological signals of each pregnancy to predict the risk of unexpected complications enabling earlier and more personalized clinical intervention.

Despite these promising growth factors, the preeclampsia diagnostics market faces challenges. Limited awareness among patients and providers and limitations in the accuracy of preeclampsia diagnostic tests are significant constraints that could potentially hinder market growth during the forecast period.

Preeclampsia Diagnostics Market Segment Analysis:

Preeclampsia Diagnostics Market by Sample Type (Blood Test and Urine Test), Product Type (Reagents & Kits, and Instruments), Mode of Testing (Laboratory-based Testing and Point-of-care Testing (POCT)), End-User (Hospitals, Specialty Clinics, Diagnostic Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)

In the sample type segment of the preeclampsia diagnostics market, the blood test category held the largest revenue share in 2024. The growth of this category is attributed to the rising use of blood tests in preeclampsia diagnostics. These tests are playing a transformative role by enabling earlier, more accurate, and accessible detection of preeclampsia even before clinical symptoms manifest. Their ability to identify risk at an early stage allows for timely intervention, significantly improving maternal and fetal outcomes.

These tests provide precise risk stratification, helping clinicians predict which patients are more likely to develop severe preeclampsia. This capability supports the efficient use of hospital resources, minimizes unnecessary interventions, and enhances patient care. Moreover, blood-based diagnostics are highly scalable and easily integrated into routine prenatal care. As awareness of preeclampsia continues to grow, and as point-of-care testing becomes more accessible even in low-resource settings the demand for these tests is expected to increase.

A major advancement in this space is the development of biomarker-based blood tests, particularly those that measure levels of placental growth factor (PlGF) and soluble fms-like tyrosine kinase-1 (sFlt-1). These biomarkers allow healthcare providers to detect preeclampsia in its early or asymptomatic stages, offering a critical tool for proactive, personalized pregnancy management.

Recent innovations in molecular diagnostics and immunoassays have led to the development of advanced blood tests for preeclampsia. For instance, companies like Thermo Fisher Scientific, PerkinElmer, and Roche Diagnostics offer blood test-based platforms for preeclampsia detection. For instance, in May 2023, the U.S. FDA approved Thermo Scientific B*R*A*H*M*S PlGF plus KRYPTOR and B*R*A*H*M*S sFlt-1 KRYPTOR novel blood-based biomarker test for the risk assessment and clinical management of preeclampsia.

Thus, all these factors are fueling the adoption of blood tests, thereby acting as a strong catalyst in the growth of the blood-based preeclampsia test, thereby driving the overall expansion of the preeclampsia diagnostics market.

North America is expected to dominate the overall Preeclampsia Diagnostics Market:

North America is projected to account for the largest share of the preeclampsia diagnostics market in 2024. This dominance can be attributed to several key factors, including the rising cases of preeclampsia, increased awareness among patients and healthcare providers, strong healthcare infrastructure, and widespread access to advanced diagnostic tools. Additionally, support from government initiatives and ongoing innovations by key players are further driving market expansion through the forecast period from 2025 to 2032.

According to the recent data provided by the Centre for Disease Control and Prevention (2022), preeclampsia is estimated to occur in 5 to 7 percent of all pregnancies in the US. Additionally, as per the same source, in the United States, the rate of preeclampsia in Black women is 60 percent higher than in White women.

Given the serious health risks it poses to both mother and baby, including preterm birth, placental abruption, and even maternal or fetal death, healthcare providers are placing increased emphasis on early screening and continuous monitoring thereby boosting the overall market of preeclampsia diagnostics across the region.

Moreover, growing product development activities among the key market players are likely to propel the revenue shares for the preeclampsia in the region. For example, In January 2024, Labcorp, a global leader in innovative and comprehensive laboratory services, announced the launch and availability of a new FDA-cleared blood test designed for the risk assessment and clinical management of severe preeclampsia, a potentially life-threatening blood pressure disorder that can occur during pregnancy and the postpartum period.

Preeclampsia Diagnostics Market Key Players:

Some of the key market players operating in the Preeclampsia Diagnostics Market include F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Labcorp, PerkinElmer, ARUP Laboratories, Siemens Healthineers AG, QuidelOrtho Corporation, Revvity, Randox Laboratories, CERCA Biotech, and others.

Recent Developmental Activities in the Preeclampsia Diagnostics Market:

  • In February 2025, Roche announced that its Elecsys(R) sFlt-1/PlGF ratio test for preeclampsia received 510(k) clearance from the U.S. FDA. The test was intended to stratify hospitalized pregnant women with hypertensive disorders into low- and high-risk groups for developing severe preeclampsia within two weeks. This enabled better prediction, earlier interventions, and reduced adverse outcomes.
  • In May 2024, Labcorp launched its first-trimester preeclampsia screening test, designed to be performed between 11 and 14 weeks of gestation to assess the risk of developing preeclampsia before 34 weeks. It was the only test of its kind available in the U.S. and applied to all pregnant individuals, including those with low- to average-risk or first-time pregnancies.

Key Takeaways from the Preeclampsia Diagnostics Market Report Study

  • Market size analysis for current preeclampsia diagnostics market size (2024), and market forecast for 8 years (2025 to 2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the preeclampsia diagnostics market
  • Various opportunities available for the other competitors in the preeclampsia diagnostics market space
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current preeclampsia diagnostics market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for preeclampsia diagnostics market growth in the coming future?

Target Audience Who Can be benefited from this Preeclampsia Diagnostics Market Report Study

  • Preeclampsia diagnostics product providers
  • Research organizations and consulting companies
  • Preeclampsia diagnostics-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in preeclampsia diagnostics
  • Various end-users who want to know more about the preeclampsia diagnostics market and the latest technological developments in the preeclampsia diagnostics market

Frequently Asked Questions for the Preeclampsia Diagnostics Market:

1. What are Preeclampsia Diagnostics?

  • Preeclampsia diagnostics refers to the methods and tools used to detect preeclampsia, a pregnancy complication characterized by high blood pressure and signs of damage to other organs, often the liver and kidneys. Diagnostics typically involve blood pressure monitoring, urine protein tests, and biomarker-based blood tests (e.g., sFlt-1/PlGF ratio) to assess the risk, presence, or severity of the condition.

2. What is the market for Preeclampsia Diagnostics Market?

  • The preeclampsia diagnostics market is estimated to grow at a CAGR of 3.67% during the forecast period from 2025 to 2032.

3. What are the drivers for the global Preeclampsia Diagnostics Market?

  • The growth of the preeclampsia diagnostics market is primarily driven by the increasing incidence of preeclampsia and its associated risk factors, along with rising awareness among pregnant women and healthcare professionals. Additionally, ongoing product development initiatives by key market players are expected to further contribute to the market's expansion during the forecast period from 2025 to 2032.

4. Who are the key players operating in the global Preeclampsia Diagnostics Market?

  • Some of the key market players operating in the preeclampsia diagnostics market include F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Labcorp, PerkinElmer, ARUP Laboratories, Siemens Healthineers AG, QuidelOrtho Corporation, Revvity, Randox Laboratories, CERCA Biotech, and others.

5. Which region has the highest share in the global Preeclampsia Diagnostics Market?

  • North America is expected to dominate the overall preeclampsia diagnostics market during the forecast period, 2025 to 2032. This dominance can be attributed to several key factors, including the rising cases of preeclampsia, increased awareness among patients and healthcare providers, strong healthcare infrastructure, and widespread access to advanced diagnostic tools. Additionally, support from government initiatives and ongoing innovations by key players are further driving market expansion through the forecast period from 2025 to 2032.

Table of Contents

1. Preeclampsia Diagnostics Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. Preeclampsia Diagnostics Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

  • 4.1. The United States
  • 4.2. Europe
  • 4.3. Japan
  • 4.4. China

5. Preeclampsia Diagnostics Market Key Factors Analysis

  • 5.1. Preeclampsia Diagnostics Market Drivers
    • 5.1.1. Rising cases of preeclampsia and associated risk factors
    • 5.1.2. Rising awareness among pregnant women and healthcare professionals
    • 5.1.3. Growing product development activities among the key market players
  • 5.2. Preeclampsia Diagnostics Market Restraints and Challenges
    • 5.2.1. Limited awareness among patients and providers
    • 5.2.2. Limitations in the accuracy of preeclampsia diagnostic tests
  • 5.3. Preeclampsia Diagnostics Market Opportunities
    • 5.3.1. Ongoing research into novel biomarkers-based preeclampsia testing and home-based testing

6. Preeclampsia Diagnostics Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Preeclampsia Diagnostics Market Assessment

  • 7.1. By Sample Type
    • 7.1.1. Blood Test
    • 7.1.2. Urine Test
  • 7.2. By Product Type
    • 7.2.1. Reagents & Kits
    • 7.2.2. Instruments
  • 7.3. Mode of Testing
    • 7.3.1. Laboratory-based Testing
    • 7.3.2. Point-of-care Testing (POCT)
  • 7.4. By End-User
    • 7.4.1. Hospitals
    • 7.4.2. Specialty Clinics
    • 7.4.3. Diagnostic Centers
    • 7.4.4. Others
  • 7.5. By Geography
    • 7.5.1. North America
      • 7.5.1.1. United States Preeclampsia Diagnostics Market Size in USD million (2022-2032)
      • 7.5.1.2. Canada Preeclampsia Diagnostics Market Size in USD million (2022-2032)
      • 7.5.1.3. Mexico Preeclampsia Diagnostics Market Size in USD million (2022-2032)
    • 7.5.2. Europe
      • 7.5.2.1. France Preeclampsia Diagnostics Market Size in USD million (2022-2032)
      • 7.5.2.2. Germany Preeclampsia Diagnostics Market Size in USD million (2022-2032)
      • 7.5.2.3. United Kingdom Preeclampsia Diagnostics Market Size in USD million (2022-2032)
      • 7.5.2.4. Italy Preeclampsia Diagnostics Market Size in USD million (2022-2032)
      • 7.5.2.5. Spain Preeclampsia Diagnostics Market Size in USD million (2022-2032)
      • 7.5.2.6. Rest of Europe Preeclampsia Diagnostics Market Size in USD million (2022-2032)
    • 7.5.3. Asia-Pacific
      • 7.5.3.1. China Preeclampsia Diagnostics Market Size in USD million (2022-2032)
      • 7.5.3.2. Japan Preeclampsia Diagnostics Market Size in USD million (2022-2032)
      • 7.5.3.3. India Preeclampsia Diagnostics Market Size in USD million (2022-2032)
      • 7.5.3.4. Australia Preeclampsia Diagnostics Market Size in USD million (2022-2032)
      • 7.5.3.5. South Korea Preeclampsia Diagnostics Market Size in USD million (2022-2032)
      • 7.5.3.6. Rest of Asia-Pacific Preeclampsia Diagnostics Market Size in USD million (2022-2032)
    • 7.5.4. Rest of the World (RoW)
      • 7.5.4.1. Middle East Preeclampsia Diagnostics Market Size in USD million (2022-2032)
      • 7.5.4.2. Africa Preeclampsia Diagnostics Market Size in USD million (2022-2032)
      • 7.5.4.3. South America Preeclampsia Diagnostics Market Size in USD million (2022-2032)

8. Preeclampsia Diagnostics Market Company and Product Profiles

  • 8.1. F. Hoffmann-La Roche Ltd.
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. Thermo Fisher Scientific Inc.
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. Labcorp
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. PerkinElmer
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. ARUP Laboratories
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. Siemens Healthineers AG
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. QuidelOrtho Corporation
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Revvity
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Randox Laboratories
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. CERCA Biotech
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: Preeclampsia Diagnostics Market in Global (2022-2032)
  • Table 3: Preeclampsia Diagnostics Market in Global by Sample Type (2022-2032)
  • Table 4: Preeclampsia Diagnostics Market in Global by Product Type (2022-2032)
  • Table 5: Preeclampsia Diagnostics Market in Global by Mode of Testing (2022-2032)
  • Table 6: Preeclampsia Diagnostics Market in Global by End-User (2022-2032)
  • Table 7: Preeclampsia Diagnostics Market in Global by Geography (2022-2032)
  • Table 8: Preeclampsia Diagnostics Market in North America (2022-2032)
  • Table 9: Preeclampsia Diagnostics Market in the United States (2022-2032)
  • Table 10: Preeclampsia Diagnostics Market in Canada (2022-2032)
  • Table 11: Preeclampsia Diagnostics Market in Mexico (2022-2032)
  • Table 12: Preeclampsia Diagnostics Market in Europe (2022-2032)
  • Table 13: Preeclampsia Diagnostics Market in France (2022-2032)
  • Table 14: Preeclampsia Diagnostics Market in Germany (2022-2032)
  • Table 15: Preeclampsia Diagnostics Market in United Kingdom (2022-2032)
  • Table 16: Preeclampsia Diagnostics Market in Italy (2022-2032)
  • Table 17: Preeclampsia Diagnostics Market in Spain (2022-2032)
  • Table 18: Preeclampsia Diagnostics Market in the Rest of Europe (2022-2032)
  • Table 19: Preeclampsia Diagnostics Market in Asia-Pacific (2022-2032)
  • Table 20: Preeclampsia Diagnostics Market in China (2022-2032)
  • Table 21: Preeclampsia Diagnostics Market in Japan (2022-2032)
  • Table 22: Preeclampsia Diagnostics Market in India (2022-2032)
  • Table 23: Preeclampsia Diagnostics Market in Australia (2022-2032)
  • Table 24: Preeclampsia Diagnostics Market in South Korea (2022-2032)
  • Table 25: Preeclampsia Diagnostics Market in Rest of Asia-Pacific (2022-2032)
  • Table 26: Preeclampsia Diagnostics Market in the Rest of the World (2022-2032)
  • Table 27: Preeclampsia Diagnostics Market in the Middle East (2022-2032)
  • Table 28: Preeclampsia Diagnostics Market in Africa (2022-2032)
  • Table 29: Preeclampsia Diagnostics Market in South America (2022-2032)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: Preeclampsia Diagnostics Market in Global (2022-2032)
  • Figure 3: Preeclampsia Diagnostics Market in Global by Sample Type (2022-2032)
  • Figure 4: Preeclampsia Diagnostics Market in Global by Product Type (2022-2032)
  • Figure 5: Preeclampsia Diagnostics Market in Global by Mode of Testing (2022-2032)
  • Figure 6: Preeclampsia Diagnostics Market in Global by End-User (2022-2032)
  • Figure 7: Preeclampsia Diagnostics Market in Global by Geography (2022-2032)
  • Figure 8: Preeclampsia Diagnostics Market in North America (2022-2032)
  • Figure 9: Preeclampsia Diagnostics Market in the United States (2022-2032)
  • Figure 10: Preeclampsia Diagnostics Market in Canada (2022-2032)
  • Figure 11: Preeclampsia Diagnostics Market in Mexico (2022-2032)
  • Figure 12: Preeclampsia Diagnostics Market in Europe (2022-2032)
  • Figure 13: Preeclampsia Diagnostics Market in France (2022-2032)
  • Figure 14: Preeclampsia Diagnostics Market in Germany (2022-2032)
  • Figure 15: Preeclampsia Diagnostics Market in United Kingdom (2022-2032)
  • Figure 16: Preeclampsia Diagnostics Market in Italy (2022-2032)
  • Figure 17: Preeclampsia Diagnostics Market in Spain (2022-2032)
  • Figure 18: Preeclampsia Diagnostics Market in the Rest of Europe (2022-2032)
  • Figure 19: Preeclampsia Diagnostics Market in Asia-Pacific (2022-2032)
  • Figure 20: Preeclampsia Diagnostics Market in China (2022-2032)
  • Figure 21: Preeclampsia Diagnostics Market in Japan (2022-2032)
  • Figure 22: Preeclampsia Diagnostics Market in India (2022-2032)
  • Figure 23: Preeclampsia Diagnostics Market in Australia (2022-2032)
  • Figure 24: Preeclampsia Diagnostics Market in South Korea (2022-2032)
  • Figure 25: Preeclampsia Diagnostics Market in Rest of Asia-Pacific (2022-2032)
  • Figure 26: Preeclampsia Diagnostics Market in the Rest of the World (2022-2032)
  • Figure 27: Preeclampsia Diagnostics Market in the Middle East (2022-2032)
  • Figure 28: Preeclampsia Diagnostics Market in Africa (2022-2032)
  • Figure 29: Preeclampsia Diagnostics Market in South America (2022-2032)
  • Figure 30: Market Drivers
  • Figure 31: Market Barriers
  • Figure 32: Marker Opportunities
  • Figure 33: PORTER'S Five Force Analysis